T-VEC治疗晚期黑色素瘤:心肺移植患者完全缓解一例
Talimogene laherparepvec (T-VEC) is a intralesional oncolytic virotherapy, licensed in the European Union for locoregional advanced melanoma of American Joint Committee on Cancer stages IIIB, IIIC and IVM1a.…
要点
- T-VEC获欧盟批准用于AJCC IIIB、IIIC和IVM1a期局部晚期黑色素瘤。
- 器官移植受者因排斥风险被所有免疫治疗临床试验排除。
- 本例心肺移植患者经T-VEC治疗11周期获完全缓解且耐受良好。
核心结论
- T-VEC对有器官移植史的晚期黑色素瘤患者可能有效且安全。
- 因情况特殊,治疗风险与获益应始终经多学科肿瘤委员会讨论。
研究设计与样本
- 个案报告:一例58岁白人男性,2014年接受心脏和肾脏移植。
- 2016年3月出现转移灶,先予5%咪喹莫特局部联合冷冻治疗,2016年11月因局部进展停药。
- 经多学科决策后接受T-VEC治疗,共11个周期。
主要发现
- T-VEC治疗11个周期后患者达到完全缓解。
- 截至2018年6月,末次T-VEC治疗周期后11个月,患者持续无瘤。
- 患者耐受良好,仅出现轻度不良事件。
- 未出现移植物排斥或移植器官功能丧失的迹象。
关键数值与推荐
- T-VEC在欧盟获批用于AJCC IIIB、IIIC和IVM1a期局部晚期黑色素瘤。
- 局部治疗采用5%咪喹莫特联合单个病灶冷冻治疗。
- T-VEC共治疗11个周期。
- 末次T-VEC治疗后11个月无瘤。
临床怎么用
- 对有器官移植史的局部晚期黑色素瘤患者,T-VEC可作为潜在治疗选择。
- 治疗前应经多学科肿瘤委员会讨论风险与获益。
- 治疗期间需监测移植物排斥和器官功能。
局限性
- 本文为单例个案报告,证据级别有限。
- 器官移植受者被排除于免疫治疗临床试验之外,缺乏群体数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Talimogene laherparepvec (T-VEC) is a intralesional oncolytic virotherapy, licensed in the European Union for locoregional advanced melanoma of American Joint Committee on Cancer stages IIIB, IIIC and IVM1a. Organ transplant recipients are currently excluded from all clinical trials dealing with immunotherapies due to the risk of transplant rejection. A 58-year-old white man with a history of heart and kidney transplantation in 2014 was diagnosed with melanoma (Breslow thickness 1·6 mm, stage pT2a) on the left arm in September 2015. In March 2016 he developed in transit metastases, and local therapy with a combination of topical imiquimod (5%) and cryotherapy of individual lesions was initiated. However, in November 2016 therapy was stopped following local progression of the metastases. An interdisciplinary decision to treat the patient with T-VEC was taken. After 11 cycles of T-VEC, the patient showed a complete response. As of June 2018, 11 months after the last treatment cycle of T-VEC, the patient continues to be tumour free. The patient tolerated the therapy well with only mild adverse events and did not show any sign of graft rejection or loss of function of the transplanted organs. We conclude that T-VEC can be a potentially effective and safe treatment in patients with a history of organ transplantation. Nevertheless, due to this special situation, the risks and benefits should always be discussed with an interdisciplinary tumour board.
引用
- Ressler J, Silmbrod R, Stepan A, et al. Talimogene laherparepvec (T-VEC) in advanced melanoma: complete response in a heart and kidney transplant patient. A case report. Br J Dermatol. 2019. PMID: 30776080. doi:10.1111/bjd.17783
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。